[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN1708301A - 褪黑激素日剂量给药单元 - Google Patents

褪黑激素日剂量给药单元 Download PDF

Info

Publication number
CN1708301A
CN1708301A CNA200380102359XA CN200380102359A CN1708301A CN 1708301 A CN1708301 A CN 1708301A CN A200380102359X A CNA200380102359X A CN A200380102359XA CN 200380102359 A CN200380102359 A CN 200380102359A CN 1708301 A CN1708301 A CN 1708301A
Authority
CN
China
Prior art keywords
container
protection
melatonin
asking
asked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200380102359XA
Other languages
English (en)
Inventor
H·W·施米德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASAT AG Applied Science and Technology
Original Assignee
ASAT AG Applied Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32233793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1708301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10250646A external-priority patent/DE10250646A1/de
Priority claimed from DE20217814U external-priority patent/DE20217814U1/de
Application filed by ASAT AG Applied Science and Technology filed Critical ASAT AG Applied Science and Technology
Publication of CN1708301A publication Critical patent/CN1708301A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Packages (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Indole Compounds (AREA)

Abstract

本发明涉及一种局部使用的药物或化妆剂的一次性容器，其包含相当于局部有效剂量而不会导致任何全身作用的单剂量褪黑激素或褪黑激素衍生物。

Description

褪黑激素日剂量给药单元
本发明涉及局部使用的药物或化妆剂的一次性容器，其包含相当于局部有效量而不会引起任何全身作用的单剂量褪黑激素或褪黑激素衍生物。
包含褪黑激素的药剂能用于各种医药和化妆目的。例如，文献DE101 10 418.9公开了局部施用于皮肤和头发的包含褪黑激素的组合物。
本发明的主题是一种局部使用的药物或化妆剂的一次性容器，其包含相当于局部有效量而不会引起任何全身作用的单剂量褪黑激素或褪黑激素衍生物。
根据本发明的一次性容器能使用局部有效而不会在正常褪黑激素血浆水平中引起不期望变化的剂量的褪黑激素或褪黑激素衍生物。根据本发明而施用的褪黑激素或褪黑激素衍生物的单剂量不会引起例如褪黑激素血浆水平的显著升高。
本申请内容中使用的表述“褪黑激素或褪黑激素衍生物”包括褪黑激素和/或褪黑激素衍生物及其盐、酯或复合物。优选的褪黑激素衍生物包括例如5-甲氧色胺、5-甲氧色氨酸、5-甲氧色醇、5-甲氧-吲哚-3-醋酸和6-羟基褪黑激素。
如本发明所述的单剂量表示具有正性化妆和/或治疗效果而在血浆水平中没有显著变化的剂量。根据本发明，褪黑激素的优选单剂量为约0.001到约1.0mg，更优选的褪黑激素单剂量为约0.01到约0.2mg。一个单剂量能每日使用一次或几次，这取决于使用的面积或药剂的预期用途。在一个优选的实施方案中，单剂量相当于日剂量，尤其优选晚间使用的日剂量。
药物或化妆剂优选以液态制剂形式存在。局部用药剂的适宜制剂的实例有溶液、混悬液、乳液、微乳、纳米系统、面霜、凝胶、洗剂、喷雾、泡沫或乳膏，以及任何能局部使用的其它制剂。药剂尤其优选以化妆溶液的形式提供。
包含在根据本发明的一次性容器中的药物或化妆剂能具有不同的褪黑激素或褪黑激素衍生物浓度，这取决于其预期用途。药剂优选包含约0.001到约0.01％(重量)，更优选约0.003到0.004％(重量)浓度的褪黑激素或褪黑激素衍生物。一个特别优选的浓度是约0.0033％(重量)。
在一个实施方案中，治疗或化妆剂包含褪黑激素或褪黑激素衍生物作为唯一的活性物质。然而，药剂也能包含一种或多种其它的活性物质例如维生素A、维生素A酸或其它的维生素A衍生物、生物素和/或银杏(gingko biloba)。
在一个优选的实施方案中，药物或化妆剂包含活性物质褪黑激素或褪黑激素衍生物与生物素和/或银杏的组合物。这个实施方案中的活性物质能以不同的剂量存在。这一组合物尤其优选的剂量是约0.05到约0.2mg，尤其优选约0.1mg的褪黑激素或褪黑激素衍生物，约0.2到约0.4mg，尤其优选约0.3mg的生物素，以及约1.3到约1.7mg，尤其优选约1.5mg的银杏。在这里银杏能包含在例如提取物尤其是干燥提取物中，和/或一种或多种成分中。
在另一个优选的实施方案中，药剂包含活性物质褪黑激素或褪黑激素衍生物和维生素A、维生素A酸或维生素A的其它衍生物的组合物。在这个优选的活性物质组合物中，褪黑激素或褪黑激素衍生物的剂量优选为约0.05到0.2mg，尤其优选约0.1mg的褪黑激素。
药物或化妆剂也能包含一种或多种化妆和/或药物助剂或添加剂，例如增稠剂、矿物质或香料。
根据本发明的组合物可用于促进毛发生长，尤其可用于防止和/或治疗男性或女性的脱发。尤其优选的适应症是男式雄激素性脱发、女式雄激素性脱发、男式弥漫脱发和女式弥漫脱发。
根据本发明的一次性容器能包含不同体积的药物或化妆剂，这取决于预期的应用或用途。在一个优选的实施方案中，该一次性容器包含约2.5到约3.5ml，优选约2.9到约3.2ml的药剂。一个特别优选的体积是约3.0ml。
治疗或化妆剂能用任何现有领域已知的适宜方法填充到容器中。该药剂优选在GMP条件下填充到容器中。在这种方式中，当施用药剂时能确保药剂是无菌的，而不会出现与细菌污染有关的问题。
根据本发明的一次性容器大体上能由任何期望的物质制成，特别是被批准用于食物产品和药物产品包装的物质。优选物质的实例是塑料和塑料混合物。尤其适合的塑料的实例是聚乙烯、聚氯乙烯、聚苯乙烯、聚丙烯、聚环烯或其混合物或共聚物，特别优选的是聚乙烯或聚环烯。
一次性容器能是透明的、非透明的、无色的或有色的，这取决于其期望的外观。任何期望的染料都能例如加入到塑料中以便得到有色的容器。如果药剂包含光敏性物质，那么优选非透明容器，因为非透明容器能额外提供光保护作用。
根据本发明的一次性容器能大体上具有任何期望的形状。图1和2显示了优选容器的实例。适宜的一次性容器优选包含容纳药剂的部分和通过预先确定的开口线(break line)与底部连接的一次性闭合部件(closure piece)。
容器的简单及安全操作通过在其端头优选具有经转动打开的一次性闭合部件而有利地得到了保证。这样，容器就能很容易地被打开。此外，打开以后，只要使用压力药剂就能暴露。此压力能例如通过使用时被手施加。这个性质允许使用者施用正确剂量的药剂并以一种目标方式将其定位。如果药剂用于头皮或头发上，那么该开口容器能被像梳子一类的物质直接导引穿过头发。这使得容器具有直接且安全的操作以及正确的药物给药。
一次性容器带有打印或凸印的文字和/或带有标签，这取决于预期的用途。
此外，两个或多个一次性容器能以可拆分的方式彼此连接。例如，5或10个容器优选彼此连接形成一列。容器或一列容器也可以被包裹起来，优选在不透光的包装中，特别优选在例如铝包中。
此处使用的表述“铝包”包括由铝制成的包，还有例如在外部或内部包有铝的包。例如由一个或多个塑料和/或纸层组成的包能用铝包衣。优选的包包含例如含有铝的层压薄片，其额外包括聚乙烯、聚酯和/或纸。
包装，尤其是不透光的包装，能贮存相当长的一段时间而不会降低药剂的有效性。此外，这样的包装能提供气体损失保护。
包裹一个或多个一次性容器的铝包能被打印上和/或提供标签，这取决于预期的用途。
在本发明的另一个实施方案中，提供了包括几列一次性容器的包装单元。
通过附图1和2及实施例对本发明进行进一步的解释。
图1显示了以可拆分方式和优选的构造彼此连接的一列5个一次性容器。
1A显示了正面图，IB是平面图，IC是侧面图，1D是斜上方的透视图。
图2A显示了一个优选构造中的单个一次性容器的正面图。2B显示了以可拆分方式彼此连接的一列10个一次性容器的正面图，2C显示了侧面图，2D显示了该列的平面图。
实施例
实施例1：根据本发明的包含褪黑激素、银杏和生物素作为活性物质的制剂组合物
该组合物包含0.05重量％的银杏干燥提取物，0.01重量％的生物素，0.0033重量％的褪黑激素以及其它添加剂、水和乙醇。组合物的pH在3.5到4之间。
实施例2：临床研究
用实施例1记载的组合物在8名健康女性患者中进行带有安慰剂对照和交叉设计的随机双盲研究。日剂量为0.1mg褪黑激素(3ml组合物)，其在每天睡觉前施用于头皮上，进行14天。
从患者中取尿样和血样，分析褪黑激素和其代谢物6-羟基褪黑激素硫酸盐。
发现用褪黑激素或安慰剂治疗的患者的褪黑激素血浆曲线相当于文献记载的内源性褪黑激素的浓度/时间曲线。这证实了局部施用包含褪黑激素的组合物14天不会改变内源性褪黑激素的分泌。
给予该组合物14天不会使褪黑激素的血浆浓度、或者是6-羟基褪黑激素硫酸盐在尿中的浓度增加到生理浓度之上。局部施用包含褪黑激素的组合物没有副作用。没有发现对反应时间或皮层兴奋参数有任何作用。
考虑到所有的事情，能肯定地断定给予该组合物不会引起任何全身作用。

Claims (29)

1.一种局部使用的药物或化妆剂的一次性容器，其包含相当于局部有效剂量而不会导致任何全身作用的单剂量褪黑激素或褪黑激素衍生物。
2.如权利要求1请求保护的容器，其特征为所述单剂量是0.001-1.0mg的褪黑激素或褪黑激素衍生物。
3.如权利要求1或2请求保护的容器，其特征为所述单剂量是0.01-0.2mg的褪黑激素或褪黑激素衍生物。
4.如权利要求1至3之一请求保护的容器，其特征为所述单剂量相当于日剂量。
5.如权利要求1至4之一请求保护的容器，其特征为所述药剂以液态制剂的形式存在。
6.如权利要求5请求保护的容器，其特征为所述液态制剂具有0.001-0.01％(重量)浓度的褪黑激素。
7.如权利要求6请求保护的容器，其特征为所述液态制剂具有0.003-0.004％(重量)浓度的褪黑激素。
8.如前述权利要求之一请求保护的容器，其特征为所述药剂包含作为唯一活性物质的褪黑激素或褪黑激素衍生物。
9.如权利要求1至7之一请求保护的容器，其特征为所述药剂包含作为活性物质的褪黑激素或褪黑激素衍生物与生物素和/或银杏的组合物。
10.如权利要求1至7之一请求保护的容器，其特征为所述药剂包含作为活性物质的褪黑激素或褪黑激素衍生物与维生素A、维生素A酸或维生素A的其它衍生物的组合物。
11.如前述权利要求之一请求保护的容器，特征是其包含2.5-3.5ml的药剂。
12.如权利要求11请求保护的容器，特征是其包含2.9-3.2ml的药剂。
13.如前述权利要求之一请求保护的容器，其特征是所述药剂在GMP条件下填充到容器中。
14.如前述权利要求之一请求保护的容器，其特征是该容器由塑料制成。
15.如权利要求14请求保护的容器，其特征是该容器由聚乙烯、聚丙烯、聚氯乙烯、聚苯乙烯或这些物质的混合物制成。
16.如权利要求1至15之一请求保护的容器，其特征是该容器是无色的。
17.如权利要求1至15之一请求保护的容器，其特征是该容器是有色的。
18.如权利要求1至17之一请求保护的容器，其特征是该容器是透明的。
19.如权利要求1至17之一请求保护的容器，其特征是该容器是不透明的。
20.如前述权利要求之一请求保护的容器，其特征是该容器端头具有通过转动打开的一次性闭合部件。
21.如前述权利要求之一请求保护的容器，其特征是打开后，当用力时所述药剂就能暴露。
22.如前述权利要求之一请求保护的容器，其特征是该容器带有打印或凸印的文字和/或带有标签。
23.如权利要求1至22之一请求保护的几个容器的一列，其以可拆分的方式彼此连接。
24.如权利要求23请求保护的一列，其特征是5个容器以可拆分的方式彼此连接。
25.如权利要求23请求保护的一列，其特征是10个容器以可拆分的方式彼此连接。
26.如权利要23至25之一请求保护的一列，其特征是其包裹在铝包中。
27.如权利要求26请求保护的一列，其特征是所述包由含有铝的层压薄片组成，并额外包括聚乙烯、聚酯和/或纸。
28.如权利要26或27请求保护的一列，其特征是所述铝包印有和/或提供有标签。
29.包含如权利要求23至28之一请求保护的几列的包装单元。
CNA200380102359XA 2002-10-30 2003-10-30 褪黑激素日剂量给药单元 Pending CN1708301A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10250646A DE10250646A1 (de) 2002-10-30 2002-10-30 Melatonin in kosmetischen Formulierungen
DE10250646.9 2002-10-30
DE20217814.5 2002-11-18
DE20217814U DE20217814U1 (de) 2002-11-18 2002-11-18 Melatonin-Tagesdosierungseinheiten
US10/353,056 US20040094449A1 (en) 2002-11-18 2003-01-29 Melatonin daily dosage units
US10/353,056 2003-01-29
PCT/EP2003/012099 WO2004039369A1 (de) 2002-10-30 2003-10-30 Melatonin-tagesdosierungseinheiten

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011101545581A Division CN102283835A (zh) 2002-10-30 2003-10-30 褪黑激素日剂量给药单元

Publications (1)

Publication Number Publication Date
CN1708301A true CN1708301A (zh) 2005-12-14

Family

ID=32233793

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200380102359XA Pending CN1708301A (zh) 2002-10-30 2003-10-30 褪黑激素日剂量给药单元
CNA2003801023960A Pending CN1708331A (zh) 2002-10-30 2003-10-30 含有褪黑素、银杏和生物素的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2003801023960A Pending CN1708331A (zh) 2002-10-30 2003-10-30 含有褪黑素、银杏和生物素的制剂

Country Status (21)

Country Link
US (3) US8062648B2 (zh)
EP (2) EP1562585B2 (zh)
JP (2) JP2006513255A (zh)
KR (2) KR20050083836A (zh)
CN (2) CN1708301A (zh)
AT (1) ATE419038T1 (zh)
AU (2) AU2003278164A1 (zh)
BR (2) BR0315927A (zh)
CA (2) CA2504341A1 (zh)
DE (1) DE50311024D1 (zh)
DK (1) DK1569724T3 (zh)
EC (2) ECSP055820A (zh)
ES (1) ES2315541T3 (zh)
HR (2) HRP20050385A2 (zh)
IS (1) IS7820A (zh)
MX (2) MXPA05004535A (zh)
NO (2) NO335547B1 (zh)
NZ (2) NZ539871A (zh)
PL (2) PL212984B1 (zh)
SI (1) SI1569724T1 (zh)
WO (2) WO2004039369A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697577A (zh) * 2015-12-09 2018-10-23 脱其泰有限责任公司 包装多单剂量容器
CN113365598A (zh) * 2018-12-05 2021-09-07 宝洁公司 用于个人健康组合物的容器

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005318934A1 (en) 2004-12-24 2006-06-29 Dolphst Pty Ltd Formulations and treatments for trichology
GB0513581D0 (en) 2005-07-01 2005-08-10 Norton Healthcare Ltd Container
ITGE20070009A1 (it) * 2007-01-24 2008-07-25 Leila Baeram Composizione cosmetica e metodo per favorire la ricrescita dei capelli.
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
CN101754753A (zh) * 2007-05-24 2010-06-23 纽约市哥伦比亚大学托管会 褪黑素的持久释放配方
IT1392903B1 (it) * 2008-07-29 2012-04-02 Marino Salin Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
US9393182B2 (en) * 2008-11-18 2016-07-19 Scarguard Labs, Llc Anti-aging product
IT1401173B1 (it) * 2010-07-26 2013-07-12 Lameplast Spa Contenitore richiudibile per prodotti fluidi, particolarmente per prodotti medicali, farmaceutici e cosmetici
PL3062797T3 (pl) 2014-05-23 2020-08-24 Triple Hair Inc. Kompozycje zmniejszające wypadanie włosów i/lub zwiększające odrastanie włosów
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
WO2016122172A1 (ko) * 2015-01-30 2016-08-04 현대약품 주식회사 멜라토닌을 포함하는 안정성이 개선된 육모, 양모 또는 발모 촉진용 조성물
US10342735B2 (en) * 2015-06-11 2019-07-09 Tokitae Llc Multi-monodose containers
US20160361232A1 (en) 2015-06-11 2016-12-15 Tokitae Llc Packaging Multi-Monodose Containers
PL3347009T3 (pl) 2015-07-08 2022-02-07 Triple Hair Inc. Kompozycja zawierająca resweratrol i melatoninę ograniczająca wypadanie włosów i/lub zwiększająca odrastanie włosów
WO2017021247A1 (en) * 2015-07-31 2017-02-09 Isdin, S.A. Anti-hair loss lotion
KR102142228B1 (ko) * 2019-12-19 2020-08-06 홍용익 초유, 비오틴 및 과라나 추출물을 함유하는 탈모 방지 및 발모 촉진 효능을 갖는 조성물 및 그의 제조방법
KR102644461B1 (ko) * 2023-08-01 2024-03-12 (주)지에프씨생명과학 경피흡수율이 우수한 모발 성장 촉진용 리포좀 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7834570U1 (de) * 1978-11-21 1979-03-22 Richardson Merrell Gmbh Mehrfachpackung
GB2079238B (en) * 1980-05-12 1984-09-05 Glaxo Group Ltd Plastics medicament containers
DK154993C (da) * 1984-01-17 1989-05-29 Pharmacia As Beholdersaet bestaaende af et antal til engangsbrug beregnede, tubeformede beholdere, der er indbyrdes forbundet
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4746674A (en) * 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
JPS61212512A (ja) * 1985-03-19 1986-09-20 Shiseido Co Ltd 養毛料
US4651361A (en) * 1985-10-07 1987-03-24 Nolan William D Portable combination hair shampoo basin and drying hood
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
US5006004A (en) * 1987-11-25 1991-04-09 The Proctor & Gamble Company Topical applicator for liquid
JPH01242516A (ja) * 1988-03-24 1989-09-27 Z Lederman Hull 養毛剤、養毛シャンプー及び養毛促進剤
JP2835970B2 (ja) * 1989-11-20 1998-12-14 株式会社コーセー 養毛料
JP2636118B2 (ja) * 1991-09-10 1997-07-30 三省製薬株式会社 育毛剤
US5750107A (en) 1993-02-12 1998-05-12 Nomura; Manabu Hair growth promoter
JPH07329994A (ja) 1994-06-10 1995-12-19 Yoshida Kogyo Kk <Ykk> 多連式並列チューブ及びその製造方法
JPH0853327A (ja) * 1994-06-10 1996-02-27 Toshihiro Matsumoto アラントインまたはその誘導体による養毛・育毛剤
ES2168392T3 (es) † 1994-12-02 2002-06-16 Kao Corp Derivados de flavanonol y compuesto estimulante para la nutricion y crecimiento del cabello que los contiene.
DE19509354A1 (de) * 1994-12-08 1996-06-13 Klett Loch Lore M Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall
DE4444238A1 (de) 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
CN2223996Y (zh) 1995-07-26 1996-04-10 沈言华 清洁灌肠器
US6602526B2 (en) * 1996-02-23 2003-08-05 Medical Doctors Research Institute Oral compositions containing lotus
FR2751539B1 (fr) * 1996-07-25 1998-12-04 Oreal Nouvelles compositions topiques comprenant de tres faibles doses de melatonine ou ses derives et leur utilisation en cosmetique
WO1998033494A1 (en) 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
EP0867181A1 (en) * 1997-03-26 1998-09-30 Franciscus Wilhelmus Henricus Maria Merkus Nasal melatonin composition
NZ501321A (en) 1997-03-26 2001-04-27 Franciscus W Nasal Melatonin composition
JPH10283531A (ja) * 1997-03-31 1998-10-23 Toshiba Corp 現金処理システム
JPH10287531A (ja) * 1997-04-14 1998-10-27 Kose Corp 毛髪用化粧料
JPH11180833A (ja) * 1997-12-16 1999-07-06 Shiseido Co Ltd 頭皮頭髪用組成物
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
DE19957710A1 (de) * 1999-11-30 2001-05-31 Asat Ag Applied Science & Tech Verwendung von Melatonin zur Behandlung der androgenetischen Alopezie
US6524619B2 (en) * 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
US6596266B2 (en) 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
DE10035735C2 (de) * 2000-07-22 2003-02-20 Wella Ag Haartonikum zur Vorbeugung oder Behandlung von Haarausfall
JP2002050328A (ja) * 2000-08-02 2002-02-15 Seiko Instruments Inc 非水電解質二次電池
GB0019327D0 (en) * 2000-08-08 2000-09-27 Buchanan Baillie Hamilton Paul Slimming system
DE20019365U1 (de) * 2000-11-15 2001-01-18 Dr. Gerhard Mann Chem.-pharm. Fabrik GmbH, 13581 Berlin Eindosis-Kunststoffbehältnis zur Aufnahme von einem flüssigen oder gelartigen pharmazeutischen Präparat
DE10110418A1 (de) 2001-03-05 2002-09-12 Asat Ag Applied Science & Tech Melatonin-Vitamin-A-Präparate
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
WO2003049687A2 (en) 2001-12-06 2003-06-19 Weller Health, Inc. Medicinal compositions & therapeutic methods
JP2005535614A (ja) * 2002-06-25 2005-11-24 コズメシューティック ソリューションズ プロプライエタリー リミテッド 局所用美容組成物
US6956266B1 (en) * 2004-09-09 2005-10-18 International Business Machines Corporation Structure and method for latchup suppression utilizing trench and masked sub-collector implantation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697577A (zh) * 2015-12-09 2018-10-23 脱其泰有限责任公司 包装多单剂量容器
CN108697577B (zh) * 2015-12-09 2021-04-30 脱其泰有限责任公司 包装多单剂量容器
CN113365598A (zh) * 2018-12-05 2021-09-07 宝洁公司 用于个人健康组合物的容器
CN113365598B (zh) * 2018-12-05 2024-08-30 宝洁公司 用于个人健康组合物的容器

Also Published As

Publication number Publication date
US8062648B2 (en) 2011-11-22
NZ539871A (en) 2008-06-30
MXPA05004537A (es) 2005-11-23
ES2315541T3 (es) 2009-04-01
US20080293803A1 (en) 2008-11-27
ECSP055820A (es) 2005-08-11
JP2006513255A (ja) 2006-04-20
BR0315878A (pt) 2005-10-04
EP1569724B1 (de) 2008-12-31
NO335547B1 (no) 2014-12-29
PL224878B1 (pl) 2017-02-28
ECSP055819A (es) 2005-08-11
EP1562585A1 (de) 2005-08-17
SI1569724T1 (sl) 2009-04-30
PL375507A1 (en) 2005-11-28
WO2004039454A1 (de) 2004-05-13
JP2006510556A (ja) 2006-03-30
KR20050083836A (ko) 2005-08-26
IS7820A (is) 2005-04-25
WO2004039369A1 (de) 2004-05-13
US20060099278A1 (en) 2006-05-11
DE50311024D1 (de) 2009-02-12
US20060035924A1 (en) 2006-02-16
CA2504361A1 (en) 2004-05-13
CN1708331A (zh) 2005-12-14
HRP20050385A2 (en) 2006-06-30
PL376226A1 (en) 2005-12-27
BR0315927A (pt) 2005-09-20
KR100849916B1 (ko) 2008-08-04
NZ539872A (en) 2007-04-27
NO20052494D0 (no) 2005-05-24
NO20052494L (no) 2005-05-24
EP1562585B1 (de) 2010-11-24
US8017645B2 (en) 2011-09-13
NO20052490D0 (no) 2005-05-24
KR20050055789A (ko) 2005-06-13
MXPA05004535A (es) 2005-11-23
NO20052490L (no) 2005-05-24
PL212984B1 (pl) 2012-12-31
EP1569724A1 (de) 2005-09-07
HRP20050386A2 (en) 2006-06-30
NO334680B1 (no) 2014-05-12
DK1569724T3 (da) 2009-03-30
AU2003283327A1 (en) 2004-05-25
EP1562585B2 (de) 2017-05-24
CA2504341A1 (en) 2004-05-13
AU2003278164A1 (en) 2004-05-25
ATE419038T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
US8017645B2 (en) Melatonin daily dosage units
CA2151122C (en) In-tandem applicator pads for therapeutic agents
US6010706A (en) Container for ascorbic acid composition
US5942531A (en) Phenolic/naphtholic retinoids for promoting skin/exoskeleton pigmentation
US20030095933A1 (en) Anti-aging skin care composition and uses thereof
WO2016010984A2 (en) Compositions and methods for treating rosacea
JPH07505644A (ja) 過飽和局所用組成物
WO2012145258A1 (en) Hair loss treatment
CA1218602A (en) Interferon gel formulations
CN102283835A (zh) 褪黑激素日剂量给药单元
US20040094449A1 (en) Melatonin daily dosage units
CA2015111A1 (en) New binary dispensor for the application of fluids, semi-fluids or semi-solids
ES2353865T3 (es) Unidades de dosificación diaria de melatonina.
US9393182B2 (en) Anti-aging product
Nashier et al. A CONCISE REVIEW ON DESIGNING OF DOSAGE FORMS
rights are reserved by Himanshu A Comprehensive Review on Pharmaceutical Liquid Dosage Form
JPS633844B2 (zh)
CA2559877A1 (en) Treatment of keratinous tissue
Lockhart et al. Introduction to the packaging of pharmaceuticals and healthcare products
ITMI950137A1 (it) Formulazioni farmaceutiche ad azione antivirale per uso topico
KR20070020421A (ko) 각질 조직의 처리
MXPA97006687A (en) Composition for the treatment of hemorrhoids and the procedure for your preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20051214